Skip to main content
. 2022 Feb 2;13(2):3930–3943. doi: 10.1080/21655979.2022.2031392

Figure 1.

Figure 1.

Serum expressions of miR-96-5p and BCL2L13 were measured in AMI-CAD patients and healthy controls. (a) The expression of miR-96-5p was dramatically decreased in serum samples from AMI-CAD patients. (b) The mRNA expression of BCL2L13 was dramatically increased in serum samples from AMI-CAD patients. (c) Western blot analysis and quantified results showed that the protein expression of BCL2L13 was dramatically increased in serum samples from AMI-CAD patients. (d) BCL2L13 expression was negatively correlated with miR-96-5p. **P < 0.01, AMI-CAD vs healthy. AMI-CAD, patients with acute myocardial infarction associated with coronary artery disease.